Defencath

Defencath is a catheter lock solution used in adult dialysis patients with central venous catheters. It helps prevent bloodstream infections by combining antimicrobial and anti-clotting effects.

Molecule Details :

  • Molecule Name :

    Taurolidine And Heparin
  • Innovator :

    CORMEDIX INC
  • Approval Date :

    15-Nov-23
  • NCE-1 Date :

    15-Nov-27
  • NCE Date :

    15-Nov-28
  • Dosage Form :

    Single Dose Vial To Instill In Central Venous Catheters
  • Strength :

    3,000 UNITS/3ML (1,000 UNITS/ML);40.5MG/3ML (13.5MG/ML), 5,000 UNITS/5ML (1,000 UNITS/ML);67.5MG/5ML (13.5MG/ML)
  • Therapeutic Category :

    Antimicrobial And Anticoagulant
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    165
  • 2026 :

    247
  • 2027 :

    274
  • 2028 :

    333
  • 2029 :

    341
  • 2030 :

    400
  • 2031 :

    457
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?